McGill Centre for Translational Research in Cancer, Canda
North Bristol NHS Trust Majorlijn Ligtenberg
Radboud University Medical Center, Netherlands Mary Porteous
University of Edinburgh
Our Science Advisory Committee consists of four independent members drawn from leading scientists broadly representing the programme diversity.
The committee meet annually, along with CRUK and PPI representation, to monitor progress and provide scientific evaluation of the CGCV program of research to the programme and work-package leads. The feedback received from the SAC is used to direct future research and program strategy.
The Patient Reference Panel (PRP) will be made up of 'research partners': patients, carers and members of the public who are affected by cancer and have an interest in genetics.
The PRP has been set up to for our research partners, working together with our research team, to look at how the CanGene-CanVar programme is set up and running, to make sure it is in the best interests of those who may be considering genetic testing, as well as making sure of good research outcomes.
Sheffield University Hospitals NHS Foundation Trust
Leeds Teaching Hospitals NHS Trust George Burghel
Manchester University NHS Foundation Trust James Drummond
Cambridge University Hospitals NHS Trust Ian Berry
Leeds Teaching Hospitals NHS Trust Andrew Wallace
Manchester University NHS Foundation Trust
CStAG is formed of NHS Clinical Laboratory Scientist representatives from across the UK.
The committee has been established from members of CanVIG, a group formed to improve the consistency of cancer genetic variant interpretation in the UK. The members are focussing the working priorities of CanVIG-UK and are an expert group of advisors supporting work-package 2.